Oppenheimer Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Oppenheimer Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,507	Closed	-$458K	–	1189
2023 Q3	$458K	Buy	10,507 +2,297	+28%	+$82K	0.01%	869
2023 Q2	$297K	Sell	8,210 -497	-6%	-$20.5K	﹤0.01%	973
2023 Q1	$324K	Buy	8,707 +1,456	+20%	+$65.5K	0.01%	951
2022 Q4	$329K	Sell	7,251 -349	-5%	-$22.6K	0.01%	946
2022 Q3	$531K	Sell	7,600 -209	-3%	-$15.5K	0.01%	818
2022 Q2	$524K	Buy	7,809 +3,859	+98%	+$245K	0.01%	842
2022 Q1	$325K	Buy	+3,950	New	+$404K	﹤0.01%	1016

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Oppenheimer Asset Management's MRTX Position: Q4 2023 in Review

Oppenheimer Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 10,507 shares — an estimated $458K sold.

Oppenheimer Asset Management first reported a position in MRTX in Q1 2022 and held it in 7 quarters. The position peaked at $531K in Q3 2022. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Oppenheimer Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Oppenheimer Asset Management sold 10,507 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $458K.
Oppenheimer Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
Oppenheimer Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $531K in Q3 2022.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Oppenheimer Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.